{"id":1380,"date":"2023-05-02T10:15:00","date_gmt":"2023-05-02T10:15:00","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/the-exercise-period-for-acarix-warrants-of-series-2022u-begins-today-2\/"},"modified":"2024-08-06T12:24:45","modified_gmt":"2024-08-06T12:24:45","slug":"the-exercise-period-for-acarix-warrants-of-series-2022u-begins-today-2","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/the-exercise-period-for-acarix-warrants-of-series-2022u-begins-today-2\/","title":{"rendered":"The exercise period for Acarix warrants of series 2022:U begins today"},"content":{"rendered":"
\n

In December 2022, Acarix AB (publ) (\u201cAcarix\u201d or the \u201cCompany\u201d) carried out a rights issue of shares and warrants of series 2022:U (the \u201cRights Issue\u201d). The exercise period for the warrants begins today, May 2, 2023, and runs up to, and including, May 16, 2023. Two warrants entitle the holder to subscribe for one (1) new share in Acarix. The subscription price per share subscribed by exercising the warrants has, in accordance with the terms of the warrants, been set at 0.37 SEK and corresponds to 70 percent of the volume-weighted average price of the Company's share on the Nasdaq First North Growth Market during a period of 10 trading days immediately preceding (and inclusive) on April 28, 2023. Upon full exercise of all warrants, Acarix will receive approximately 21.6 MSEK before deductions for issue costs.<\/strong><\/p>\n<\/div>\n

\n

Summary of instructions and important dates<\/strong>
Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise well before May 16, 2023. Warrants that have not been exercised or sold before then expire without value. Holders who do not wish to exercise their warrants can sell them. Trading in the warrants continues until May 12, 2023.<\/p>\n

Detailed information and instructions for subscription<\/strong>
Exercise of nominee-registered warrants<\/strong><\/em>
Holders who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before 16 May 2023 as different nominees have different processing times.<\/p>\n

Exercise of directly registered warrants<\/strong><\/em>
Holders who have their holding of warrants directly registered (holding in VP account) must notify the exercise of warrants by submitting an application form for the exercise, so that the application form is received by the issuing agent Hagberg & Aneborn Fondkommission no later than May 16, 2023.<\/p>\n

The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.acarix.com<\/a>, www.hagberganeborn.se<\/a>, www.redeye.se<\/a>). Please note that payment for the new shares must be received by Hagberg & Aneborn Fondkommission no later than May 16, 2023 in accordance with the instructions on the application form.<\/p>\n

Trading in warrants<\/strong>
Holders who do not wish to exercise their warrants may sell them on the Nasdaq First North Growth Market. The warrants are traded until and including 12 May 2023 under the short name ACARIX TO 2022U and with ISIN SE0019176256. Warrants that are not exercised by May 16, 2023 or sold by May 12, 2023 at the latest expire without value.<\/p>\n

Outcome and delivery of new shares<\/strong>
The outcome of the exercise of the warrants will be published via press release around May 19, 2023. Shares that have been subscribed and paid for may be registered in the subscriber's securities depository as interim shares (IA) until registration of the issue is completed with the Swedish Companies Registration Office, whereupon interim shares are automatically changed to ordinary shares in Acarix.<\/p>\n

Number of warrants and possible issue proceeds<\/strong>
The number of warrants amounts to 116,958,915. Upon full exercise of all warrants, Acarix will receive approximately 21.6 MSEK before issue costs. Upon full exercise of all warrants, the number of shares in Acarix will increase by 58,479,457 shares to a total of 431,810,566 shares, and the share capital will increase by approximately SEK 584,794.57 to approximately SEK 4,318,105.66. This entails a dilution of approximately 13 percent, taking into account shares issued on April 4, 2023, based on the number of shares in Acarix after full exercise of all warrants.<\/p>\n

Complete terms and conditions for the warrants<\/strong>
Complete terms and conditions for the warrants are available on the Company's website and in the prospectus prepared by the board of Acarix in connection with the rights issue in 2022. The prospectus is available on the Company's, the issuing agent's and Redeye's respective websites. It is also available on the Swedish Financial Supervisory Authority's website www.fi.se<\/a>.<\/p>\n

Invesor presentations<\/strong>
Acarix will present at Redeye Investor Forum Online on May 4, Redeye Medtech event on May 10 and Redeye Live Q on May 11. Information about the events is available on Redeye's website. Additional investor presentations may be organized during the exercise period. The invitation to these will be presented on the respective websites of Acarix and Redeye.<\/p>\n

Advisers<\/strong>
Redeye AB is acting as financial adviser and Hagberg & Aneborn Fondkommission AB is acting as issuing agent in connection with the transaction.<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46\u00a0730 770283, email helen.round@acarix.com<\/a>\u00a0
Christian Lindholm, CFO, phone +46\u00a0705 118333, email christian.lindholm@acarix.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor\u00aeSystem is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se<\/a>) is Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a>.\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
The exercise period for Acarix warrants of series 2022:U begins today<\/a><\/p>\n<\/div>\n